Skip to main content
. 2019 Feb 15;10(14):1399–1406. doi: 10.18632/oncotarget.26659

Figure 2. In vivo murine efficacy of anti-KLRG1 antibody.

Figure 2

(A and B) Inhibition of metastasis in 4T1 breast cancer model.(A) No effect on primary tumor growth. (B) Reduction in lung weights and nodule counts in anti-KLRG1 antibody treated mice. (C–F) Reduction in tumor growth and improvement in survival with anti-KLRG1 + anti-PD-1 combination therapy in (C, D) MC38 colon cancer model and (E, F) B16F10 melanoma model. Survival P-values compare combination therapy to control antibody. P-values: * <0.05, ** <0.01, *** <0.001, **** <0.0001.